AN INDEPENDENT SUPPLEMENT DISTRIBUTED ON BEHALF OF MEDIAPLANET, WHICH TAKES SOLE RESPONSIBILITY FOR ITS CONTENTS
Communities are making all the difference in the HIV response Communities have always played a huge part in the response to HIV. People coming together, organising themselves, telling truth to power, and demanding their right to health. For people most vulnerable to HIV, it is no exaggeration to say that communities often make the difference between life and death.
F
or young women and girls, for marginalised, vulnerable groups of people such as gay men and other men who have sex with men, transgender people, s e x worker s, p e ople who u s e drugs, prisoners and migrants, the pathway to health is not always as clear-cut as it should be. S t ig m a a nd d i sc r i m i n at ion, repressive laws, ignorance and even hate, can all prevent vulnerable people from accessing life-saving prevention, treatment and care. Communities are fighting for HIV services
This is where communities often step in. Communities of people living with HIV, of marginalised and vulnerable groups, of women and of young people, lead and sustain the delivery of peer-to-peer HIV services. They also defend human rights and advocate for access to essential services. They fight every day to keep people at the centre of decisionmaking and implementation and help to make sure that no one is left behind. Women and girls are the backbone of care support in their families and communities, providing unpaid and often undervalued work in caring
Communities must have the space and power to voice their demands and write their own solutions. for children, the sick, the elderly and the disabled. They often underpin fragile social support systems. The involvement and leadership of women is vital in the response to HIV and we must support them to leverage their potential. Community-based services often support fragile public health systems by filling critical gaps; they are led by, or connect, women and other marginalised populations; they provide services that complement clinic-based care and they extend the reach of healthcare to groups that would otherwise fall through the gaps.
and write their own solutions. In 2016, world leaders signed the United Nations Political Declaration on Ending AIDS, which recognised the essential role that communities play in advocacy, participation in
WINNIE BYANYIMA Executive Director UNAIDS the coordination of AIDS responses and service delivery. Moreover, they recognised that community responses to HIV must be scaled up and committed to at least 30% of services being community-led by 2030. Most countries are nowhere near reaching that commitment and where investment in communities is most lacking, there is often weaker progress against HIV and other health challenges.
Communities stand ready to play their part in building healthier and more resilient societies, but they need our support. On World AIDS Day, let’s celebrate communities, recognise the essential role they play in the response to HIV, and commit to meeting the promises made to them. Read more at globalcause.co.uk
Reduced funding is a barrier to HIV At a time when reduced funding is putting the sustainability of HIV services in jeopardy, community activism remains critical. Indeed, a greater mobilisation of communities is urgently required and barriers that prevent them delivering services and seeking funds must be dismantled. Communities must have the space and power to voice their demands
7 October, 2019 - Zanzibar, Tanzania - Soud Khamis Soud, a volunteer at ZAPHA+ and a young person living with HIV
Specialist Biotech company, based in Switzerland and the Netherlands. R&D of preventative vaccines against human infectious and life disabling diseases. Unique and proven proprietary virosome technology platform with viral membrane proteins and ability to incorporate and anchor antigens and adjuvants on one enveloped virus like particle. Virosome vaccines: Good safety and immunogenicity track record, GMP ready and thermostable. Vaccine candidates in development: Infectious diseases: Malaria, HIV, Chikungunya, Influenza, RSV Immunotherapy partnerships in Oncology and Allergies. HIV vaccine candidate: Having shown significant protection in non-human primates against multiple live viral challenges, Mymetics thermostable HIV vaccine candidate is currently in a final pre-clinical study and preparing for clinical trails and supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number U19AI142636.
2 GLOBALCAUSE.CO.UK
MEDIAPLANET